TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3884152
Drug: 200 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2/day orally
Study: 3884152
Drug: 100 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2/day iv
Study: 3884152
Drug: Oral VP‐16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VP‐16
Study: 24392497
Drug: Anesthetic mouthwash
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic mouthwash along with oral analgesic post biopsy (Group B)
Study: 24392497
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic post biopsy, except when required (Group A)
Study: 17970786
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Study: 17970786
Drug: Standard-dose (STD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (STD) chemotherapy with six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Study: 17970786
Drug: Standard-dose (STD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (STD) chemotherapy
Study: 15997634
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg bid (group 1)
Study: 15997634
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg bid + nitrendipine 20 mg qd (group 2)
Study: 15997634
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (enalapril + nitrendipine)
Study: 15997634
Drug: Monotherapy (enalapril)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (enalapril)
Study: 2054268
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg as enteric coated granules administered alone
Study: 2054268
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg as enteric coated granules administered after ranitidine 300 mg
Study: 29778344
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with pharmacist intervention (medication reconciliation, medication review, participation in ward rounds)
Study: 27648957
Drug: Ordered mesoporous
Normalized name: Orderable Drug Form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordered mesoporous silica formulation of fenofibrate
Study: 24613691
Drug: PVS‐10200 (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVS‐10200 (low-dose cohort A)
Study: 24613691
Drug: PVS‐10200 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVS‐10200 (high-dose cohort B)
Study: 17389731
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum digoxin concentrations (SDC) (0.5-0.9 ng/mL)
Study: 17389731
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum digoxin concentrations (SDC) (≥ 1 ng/mL)
Study: 17389731
Drug: Low-dose digoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose digoxin (≤ 0.125 mg/d)
Study: 7857343
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of pidotimod (200 mg in bolus)
Study: 7857343
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of pidotimod at 200, 400, and 800 mg
Study: 7857343
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of pidotimod at 50, 100, and 200 mg (12 volunteers/group) twice a day for 15 days
Study: 7857343
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of pidotimod (800 mg) in different formulations (sachets, vials, tablets)
Study: 2575335
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (200 mg/day, corresponding to 30 mg zinc metal)
Study: 23400965
Drug: H₂-water (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: H₂-water (1,000 mL/day for 48 weeks)
Study: 8640816
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin C 100 mg/day, vitamin E 280 mg/day, beta-carotene 25 mg/day) for 20 weeks
Study: 6752720
Drug: Alkylating agents
Normalized name: ALKYLATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agents (melphalan and chlorambucil)
Study: 6752720
Drug: Surgery or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery or radiation or both without alkylating agents
Study: 6752720
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (alkylating agents)
Study: 30669181
Drug: i.v. fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fluid administration
Study: 30372711
Drug: Desoximetasone spray
Normalized name: desoximetasone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone spray 0.25% with twice-daily telephone calls to discuss treatment adherence
Study: 30372711
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment adherence support (control group)
Study: 26827913
Drug: PSX1002-GB 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSX1002-GB 12.5 μg
Study: 26827913
Drug: PSX1002-GB 25
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSX1002-GB 25 μg
Study: 26827913
Drug: PSX1002-GB 50
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSX1002-GB 50 μg
Study: 26827913
Drug: PSX1002-GB 100
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSX1002-GB 100 μg
Study: 24500245
Drug: SAMe 1,600‐3,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 1,600‐3,200 mg/d
Study: 19683590
Drug: Aclidinium (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (all doses)
Study: 15716198
Drug: Alfuzosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (5 mg twice daily)
Study: 15716198
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg once daily)
Study: 7626351
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment (group 2)
Study: 7626351
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic medication (group 1)
Study: 7626351
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (group 3)
Study: 20394251
Drug: PCA remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA remifentanil 0.5 microg/kg as a loading bolus, 0.25 microg/kg PCA bolus, continuous infusion of 0.05 microg/kg/min
Study: 12147804
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/day p.o.)
Study: 7619749
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/sqm day 1) + etoposide (100 mg/sqm days 1-3) every 3 weeks (PE)
Study: 7619749
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/sqm every 4 weeks) + mitomycin-C (8 mg/sqm days 1-29-71) + vindesine (3 mg/sqm days 1-8-15-22) (MVP)
Study: 7619749
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/sqm day 1) + mitomycin-C (6 mg/sqm day 1) + ifosfamide (3 mg/sqm day 2) every 3 weeks (MIC)
Study: 2797631
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of aspirin per day
Study: 2797631
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of aspirin per day
Study: 2797631
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin per day
Study: 31729443
Drug: Biophysical propensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophysical propensity scales as input features for ML methods
Study: 31729443
Drug: Non-linear ML
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-linear ML methods
Study: 29076670
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa 1g twice a day for 12 weeks
Study: 26063318
Drug: Standard Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Western Medicine Treatment (SWMT)
Study: 23952636
Drug: Tirasemtiv (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv (375 mg daily for two weeks, with and without riluzole; 500 mg daily in two divided doses for three weeks)
Study: 17089219
Drug: Thermal mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mineral water treatment
Study: 19197573
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water treatment (Control)
Study: 15505457
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine infusion (90 seconds)
Study: 15505457
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (90 seconds)
Study: 11678162
Drug: Timolol GS
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol GS (TIMOPTIC‐XE), 0.5% once daily
Study: 11678162
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate ophthalmic solution, 0.5% twice daily
Study: 26853333
Drug: Surgical staging
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical staging followed by chemoradiation therapy (CRT) (arm A)
Study: 26853333
Drug: Clinical staging
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical staging followed by chemoradiation therapy (CRT) (arm B)
Study: 26178889
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg intravenously per year for two years)
Study: 16731539
Drug: TAM‐LHRHa (LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM‐LHRHa (LHRH agonist plus tamoxifen)
Study: 8143951
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of alcohol
Study: 3548626
Drug: Oral ketoconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketoconazole, 400 mg/d
Study: 31549147
Drug: 12-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month treatment regimen containing clofazimine (CFZ)
Study: 31549147
Drug: 18-month treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18-month treatment regimen (control group)
Study: 21171261
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg qd
Study: 21171261
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tamsulosin and tolterodine 2 mg bid
Study: 10499246
Drug: Postmastectomy locoregional
Normalized name: GELATIN,ABSORBABLE PROSTATECTOMY CONE,SZ 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmastectomy locoregional radiation therapy
Study: 7798683
Drug: Active postexposure
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active postexposure prophylaxis with two different vaccines
Study: 7798683
Drug: Passive-active immunoprophylaxis
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive-active immunoprophylaxis with high-dose hepatitis B immune globulin
Study: 30959314
Drug: Clarithromycin treatment
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin treatment (14-day duration)
Study: 27730425
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) injections and short pulse focal/grid laser photocoagulation
Study: 26176347
Drug: Atropine (pre-treatment)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine (pre-treatment)
Study: 26176347
Drug: Ondansetron (pre-treatment)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (pre-treatment)
Study: 22762238
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of neuromuscular electrical stimulation (NMES) and balloon dilatation for 4 months
Study: 22762238
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of NMES and balloon dilatation
Study: 19634161
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) with daily subcutaneous amifostine (500 mg)
Study: 19634161
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (AUC 1.5) and paclitaxel (45 mg/m2) without amifostine
Study: 19634161
Drug: Weekly carboplatin/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly carboplatin/paclitaxel with concomitant boost radiation
Study: 19634161
Drug: Weekly carboplatin/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly carboplatin/paclitaxel with daily subcutaneous amifostine
Study: 17526165
Drug: Spleen-invigorating Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen-invigorating Prescription (SIP), orally, twice a day for 6 months
Study: 17526165
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: intramuscular injection with human interferon alpha 1b, 3 times a week
Study: 15063521
Drug: Low-intensity pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pulsed ultrasound (LIPUS) for delayed union treatment
Study: 7908268
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (budesonide) plus beta 2-agonist (salbutamol) 0.2 mg, t.i.d.
Study: 7908268
Drug: Beta 2-agonist
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonist (salbutamol) alone
Study: 3465425
Drug: Vigabatrin (gamma-vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2-4 g for 4 months
Study: 3465425
Drug: Vigabatrin (gamma-vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day for 3 months
Study: 3465425
Drug: Vigabatrin (gamma-vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 4 g/day
Study: 3465425
Drug: Vigabatrin (gamma-vinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (gamma-vinyl GABA) at a daily dose of 2 g/day
Study: 30567490
Drug: Hydromorphone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.2 mg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Study: 30567490
Drug: Sufentanil (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (3.0 μg/kg) + dezocine (0.5 mg/kg) + ramosetron (0.6 mg) diluted with normal saline to 200 mL
Study: 26551550
Drug: Ramosetron 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 2.5 μg once daily for 12 weeks
Study: 18626707
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone administered 1 hour before surgery and 12 hours after the first administration
Study: 10492054
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone
Study: 18626707
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the same intervals as oxycodone
Study: 15447698
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg (tablets)
Study: 15447698
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg (wafers)
Study: 11228217
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg triptorelin (conventional dose)
Study: 11228217
Drug: 1.87 mg
Normalized name: proline 1.87 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.87 mg triptorelin (low dose)
Study: 11228217
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of triptorelin
Study: 3535002
Drug: Placebo/metoprolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/metoprolol 10 mg i.v. in patients with normal UAE
Study: 3535002
Drug: Placebo/metoprolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/metoprolol 10 mg i.v. in patients with incipient nephropathy
Study: 3535002
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg/24 h and hydroflumethiazid 25 mg/24 h during long-term treatment
Study: 16399110
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) administered intravenously at a dosage of 2.0 mg/kg/h starting 12 hours before surgery until postoperative day 2
Study: 15276504
Drug: Bradykinin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin infusion (25 microg for 7 minutes)
Study: 15276504
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bradykinin infusion)
Study: 11422001
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg tablet every 12 h for 8 days) + Almotriptan (12.5 mg tablet on day 8)
Study: 11422001
Drug: Almotriptan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (12.5 mg tablet on day 8)
Study: 9266290
Drug: Nisoldipine coat-core
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat-core formulation
Study: 9266290
Drug: Intravenous formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous formulation
Study: 7905660
Drug: Ebrotidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (800 mg) plus ASA (500 mg)
Study: 7905660
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ASA (500 mg)
Study: 3641787
Drug: Fosfomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin plus ampicillin (4 g fosfomycin every 8 h and 1 g ampicillin every 6 h)
Study: 3641787
Drug: Gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin plus ampicillin (80 mg gentamicin every 8 h and 1 g ampicillin every 6 h)
Study: 31880993
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg BW oyster meat preload
Study: 31880993
Drug: 0.1 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g/kg BW oyster meat preload
Study: 31880993
Drug: 0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/kg BW (control)
Study: 9607383
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg irbesartan
Study: 9512880
Drug: Enrolled in
Normalized name: Enromed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled in vaccine trial
Study: 9512880
Drug: Not enrolled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not enrolled in vaccine trial
Study: 623136
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (hydrochlorothiazide + alpha methyldopa)
Study: 31265476
Drug: Self-administered exercise
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered exercise program
Study: 22231150
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids
Study: 20884007
Drug: Rosuvastatin (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5, 10, or 20 mg) for a mean period of 29 weeks
Study: 19349630
Drug: Triple-combination pharmacotherapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination pharmacotherapy (nicotine patch, nicotine oral inhaler, and bupropion ad libitum)
Study: 19349630
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch alone for a standard 10-week course
Study: 19349630
Drug: Triple-combination pharmacotherapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination pharmacotherapy
Study: 17873238
Drug: Rivaroxaban 30
Normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 30 mg
Study: 14985222
Drug: Zinc alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc alone (10 mg Zn; n = 81)
Study: 11371689
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir (ABC) 600 mg twice daily
Study: 2647807
Drug: Analgesic imagery
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic imagery
Study: 30269035
Drug: Cranberry diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry diet (animal-based diet plus 30 g/day freeze-dried whole cranberry powder)
Study: 30269035
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (animal-based diet plus 30 g/day placebo powder)